



Serotonin and Receptors in Disease and Health

Guest Editor:

Dr. Stephanie Watts

Department of Pharmacology
and Toxicology, Michigan State
University, East Lansing, MI
48824, USA

Deadline for manuscript
submissions:

closed (30 April 2023)

Message from the Guest Editor

Dear Colleagues,

Serotonin (5-hydroxytryptamine, 5-HT) has come a long way since its discovery in the 1940s, isolated from the blood as a vasoactive substance. We invite you to share your work on 5-HT and its receptors, now 13 subtype members strong, in any area of research (cardiovascular, neuroscience, immune, etc.), as well as share information about tools that could support our 5-HT community.

With this Special Issue of *Biomedicines*, we focus on the current understanding and future research directions regarding the role of 5-HT and its receptors as key players in disease. We warmly welcome original research and review articles relating to this hot topic.

Dr. Stephanie Watts

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)